All the stuff in peoples' protocols are just made up. There is exactly zero science on using those peptides together or sequentially.
SS-31 is approved for a genetic mitochondrial dysfunction disorder, Barth syndrome, it has had a few trials in humans for various purposes, but the results were generally disappointing and they more or less gave up on future trials on more general purpose therapies with it. Apart from animal studies, I am not aware of any ongoing drug development for it for anything else apart from Barth syndrome.
Mots-c or a slight variant on it, CB4211 has had one phase 1 trial and is supposed to be having a phase 2 trial for fatty liver disease. That's it for human trials.
For both peptides there are various different studies showing effects in mice or cells, that sound interesting, but less than one in 10 interesting drugs turn out to work when tested in clinical trials in humans, and assuming cell or animal studies will show the same effects in humans is not a safe or reasonable assumption, given the less than 1 in 10 figure mentioned. As far as I know there is no cell or animal evidence for using them together on in sequence either.
Someone at some point obviously had a theory as to why they might work in that sequence, and it makes a good sounding story to sell peptides, but it has no scientific validity.
Both peptides do have real biological effects, I think SS-31 has had enough trials to show it does not do the things they hoped it would like treat heart failure, but it did not cause harm in the trials.
Mots-c sounds even more interesting, acting like exercise in a pill for mice, but a single phase 1 study for liver disease does not in any way prove it is safe in humans or has the same metabolic benefits it does in mice. There is a small chance it will eventually be proven to be safe and useful, but it has a lot of steps to get through before that can happen, and would require a drug company to believe it is good enough to be worth spending millions on trials,. One thinks that is the case for fatty liver , and is doing development work on it, but even those trials are not going to prove it helps for other issues.